Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
about
Use of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewNonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitorsIncreased risk of high-grade hemorrhage in cancer patients treated with gemcitabine: a meta-analysis of 20 randomized controlled trialsShort-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysisRisk of thyroid dysfunction in patients with solid tumors treated with VEGF receptor tyrosine kinase inhibitors: a critical literature review and meta analysis.A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic ReviewNon-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesMolecularly targeted therapies for advanced or metastatic non-small-cell lung carcinomaComparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trialsNovel targets for VEGF-independent anti-angiogenic drugs.Targeting VEGF in lung cancer.Sorafenib in non-small cell lung cancer.Safety and feasibility of targeted agent combinations in solid tumours.Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer.Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.Prospective study of prognostic value of Raf kinase inhibitory protein and pretreatment plasma Epstein-Barr virus DNA for distant metastasis in locoregionally advanced nasopharyngeal carcinoma.A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.Sorafenib for lung cancer: is the "Battle" still open?Newly developed anti-angiogenic therapy in non-small cell lung cancer.Best Practices in Treatment Selection for Patients With Advanced NSCLC.Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.[Interstitial lung disease associated with lung cancer treatment].
P2860
Q27022535-DF2936DD-333E-4E30-AFC7-97DAFF8FB2C4Q27693185-A6F6E540-0513-4080-BAF5-F92B2C35EF39Q28533753-E74BCE2E-FFAA-47C0-A640-01D092958154Q30240170-7FCE07CC-EA0E-4E98-B578-58BDDA809913Q33421419-4C40E6F3-4928-4CBC-8910-7240787DC915Q35187896-E0FEB14B-3385-4F4B-AFFB-93628D68395FQ36241287-5578BF1B-CE6F-4608-B51C-81CB62C05841Q36270115-5D0E1B39-32F9-4316-815E-C8EF1F8E96F2Q36850900-099800B1-D90F-4D6F-9013-0CF14F518F3CQ36859958-2B53528F-7B4E-4864-A2BE-24AE5E32528CQ37701719-3A67569E-07BD-42B5-B0AA-E28767543F6CQ37984612-8ABCC87D-76A2-45D6-BBC7-B0A84C7F7584Q37996080-1832FAC4-8314-4B46-B69E-794F907B554EQ38020917-DBD7B31E-D833-4A9B-A9D6-F78B1F3103ABQ38077440-6B26E89D-DD3C-466F-B2FE-E4FB14CB8FF5Q38110796-E32C37A8-FB9A-46E5-9F79-F0D70043FE50Q38199178-307F14C3-B1B6-4CB3-9CF3-75C015C704FCQ38267043-49DCC286-965B-4524-9920-E6B26D15ACA4Q39362619-CDA496AC-1BFA-40E1-8D77-91CEF7243880Q43832494-2D58C746-877D-4B91-82FB-E1DED41666C2Q44442164-7F66D4F3-A2EF-4E92-8FD5-7BA136ED5CDEQ52627568-4D1AA733-E97A-47C6-B831-A24CB1DFE276Q52668159-EA9613C2-098C-479A-ABE1-BF3E48BEB38EQ52814108-6C4B5AB7-ED02-48CA-8FD1-19AE655F2B66Q55069554-076B23D5-E842-4550-AED0-4660EC1C0C07Q55465401-F904E28D-FFA8-4443-A82B-3BA70E48E92E
P2860
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Sorafenib in combination with ...... : a randomized phase II study.
@en
Sorafenib in combination with ...... : a randomized phase II study.
@nl
type
label
Sorafenib in combination with ...... : a randomized phase II study.
@en
Sorafenib in combination with ...... : a randomized phase II study.
@nl
prefLabel
Sorafenib in combination with ...... : a randomized phase II study.
@en
Sorafenib in combination with ...... : a randomized phase II study.
@nl
P2093
P2860
P50
P356
P1433
P1476
Sorafenib in combination with ...... : a randomized phase II study.
@en
P2093
C Gridelli
F Morgillo
F de Marinis
R Mattioli
P2860
P304
P356
10.1093/ANNONC/MDQ630
P577
2011-01-06T00:00:00Z